Results 291 to 300 of about 48,696 (305)
Some of the next articles are maybe not open access.
The Antithrombotic Effect of Dabigatran
Canadian Journal of Cardiology, 2014A 72-year-old man presented to the emergency department because of a sudden onset of left-sidedweakness. The patient had his first cerebral vascular accident at the age of 49 years. Atrial fibrillation (AF) and hypertension were diagnosed at that time.
Hsueh Han Wang +2 more
openaire +3 more sources
Drug Research, 2019
Abstract Purpose Due to bioanalytical limitations it was previously not possible to evaluate the pharmacokinetics of dabigatran etexilate. We have developed validated methods to assay dabigatran etexilate, unconjugated dabigatran, and total dabigatran that will allow for a complete investigation into the pharmacokinetics of dabigatran etexilate ...
Zia Tayab, Mohammed Bouhajib
openaire +3 more sources
Abstract Purpose Due to bioanalytical limitations it was previously not possible to evaluate the pharmacokinetics of dabigatran etexilate. We have developed validated methods to assay dabigatran etexilate, unconjugated dabigatran, and total dabigatran that will allow for a complete investigation into the pharmacokinetics of dabigatran etexilate ...
Zia Tayab, Mohammed Bouhajib
openaire +3 more sources
2017
With the limited availability of reversal agents, it may be difficult to treat a patient who has overdosed on a direct oral anticoagulant (DOAC). Treatment of these patients may be guided by time elapsed since ingestion, laboratory values, and overall clinical stability.
openaire +2 more sources
With the limited availability of reversal agents, it may be difficult to treat a patient who has overdosed on a direct oral anticoagulant (DOAC). Treatment of these patients may be guided by time elapsed since ingestion, laboratory values, and overall clinical stability.
openaire +2 more sources
Total Synthesis of Dabigatran Revisited; Synthesis of Amidine‐Tosylated Dabigatran
ChemistrySelect, 2019AbstractThe total synthesis of a new dabigatran derivative featuring a tosyl protecting group at the amidine group of dabigatran was explored. During the course of this work, different new synthetic pathways towards dabigatran intermediates are investigated and known concepts revisited.
Stefan Jopp +6 more
openaire +2 more sources
Journal of Medicinal Chemistry, 2012
Recent studies have revealed that compounds believed to be highly selective frequently address multiple target proteins. We investigated the protein interaction profile of the widely prescribed thrombin inhibitor dabigatran (1), resulting in the identification and subsequent characterization of an additional target enzyme.
Mathias Dreger +11 more
openaire +2 more sources
Recent studies have revealed that compounds believed to be highly selective frequently address multiple target proteins. We investigated the protein interaction profile of the widely prescribed thrombin inhibitor dabigatran (1), resulting in the identification and subsequent characterization of an additional target enzyme.
Mathias Dreger +11 more
openaire +2 more sources
Bloedingsrisico’s van dabigatran
Huisarts en wetenschap, 2015Dabigatran beschermt beter tegen CVA’s dan warfarine bij patienten met non-valvulair atriumfibrilleren. Over de veiligheid van het middel zijn de berichten minder positief. Zo wordt dabigatran steeds vaker in verband gebracht met een verhoogde kans op ernstige bloedingen.
openaire +2 more sources
Idarucizumab for the Reversal of Dabigatran
Annals of Emergency Medicine, 2017Michael Gottlieb, Basem F. Khishfe
openaire +3 more sources